334 related articles for article (PubMed ID: 29661738)
1. Overexpression of Lox in triple-negative breast cancer.
Leo C; Cotic C; Pomp V; Fink D; Varga Z
Ann Diagn Pathol; 2018 Jun; 34():98-102. PubMed ID: 29661738
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
3. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
4. Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers.
Abd El-Hafez A; Shawky Mohamed Ael-A; Elesawy BH
Asian Pac J Cancer Prev; 2013; 14(2):1037-41. PubMed ID: 23621182
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
6. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
7. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
8. Activation of epithelial-mesenchymal transition process during breast cancer progression - the impact of molecular subtype and stromal composition.
Markiewicz A; Topa J; Popęda M; Szade J; Skokowski J; Wełnicka-Jaśkiewicz M; Żaczek A
Acta Biochim Pol; 2021 Aug; 68(3):385-392. PubMed ID: 34432400
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.
Nabi MG; Ahangar A; Wahid MA; Kuchay S
Niger J Clin Pract; 2015; 18(3):381-6. PubMed ID: 25772923
[TBL] [Abstract][Full Text] [Related]
11. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
12. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
[TBL] [Abstract][Full Text] [Related]
13. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
16. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
19. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
20. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]